Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines using ribonucleic acid interference (RNAi) to silence genes that cause various diseases. As a wholly owned subsidiary of Novo Nordisk, Dicerna is dedicated to driving advancements in the field of RNAi therapeutics. With a strong following of over 30,000 followers on LinkedIn, Dicerna Pharmaceuticals is committed to making a positive impact in the healthcare industry. Visit their corporate website for more information.

Nappa Electrical Contractors is honored to have our design/build project for Dicerna Pharmaceuticals, Inc. featured as "Project of the Month" in the July ...

Almost two years after it agreed to buy Lexington-based Dicerna Pharmaceuticals Inc. for $3.3 billion, Novo Nordisk has scored its first ...

Dicerna Pharmaceuticals, Inc. | 30903 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving ...

Dicerna Pharmaceuticals, Inc.

Find contacts at this company